Delivering new horizons for heart health

Beyond statins

Esperion is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density, lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Many patients with elevated risk of heart disease are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies. Our lead product candidate, ETC-1002, is a first-in-class orally available small molecule designed to significantly lower elevated levels of LDL-C and improve other cardiometabolic risk markers — without the side effects associated with statin use.

Clinical Studies

Esperion recently announced positive top-line results from ETC-1002-007, a Phase 2a clinical study of ETC-1002 when added to statin therapy in patients with elevated levels of LDL-C.  The study demonstrated that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10 mg of atorvastatin (p<0.0001).  ETC-1002 was well tolerated over eight weeks of treatment when added to statin and no serious adverse events were reported.  Learn more about our current and completed clinical studies and our product development pipeline.


Meet Esperion

Our founder, executive chairman and chief scientific officer, Roger Newton, co-discovered the statin marketed as Lipitor®—the most prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history. Learn more about our management team’s track record of success.